Targeting a protein that drives pancreatic cancer growth
Inhibitors of the G protein GNAS which drives pancreatic tumorigenesis
This study is looking at ways to create new treatments for pancreatic cancer by targeting a specific protein that helps tumors grow, with the hope of finding better options for patients dealing with this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10788408 on NIH RePORTER |
What this research studies
This research focuses on developing inhibitors for the G protein Gαs, which is known to play a significant role in the development of pancreatic tumors. By understanding how mutations in the GNAS gene contribute to cancer progression, the researchers aim to create targeted therapies that can effectively disrupt this process. The approach involves studying the molecular mechanisms of Gαs activation and designing drugs that can selectively bind to the mutated protein, potentially leading to new treatment options for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those with mutations in the GNAS gene.
Not a fit: Patients with pancreatic cancer who do not have GNAS mutations may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that significantly improve outcomes for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be viable.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Shokat, Kevan M. — University of California, San Francisco
- Study coordinator: Shokat, Kevan M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.